CG
NBIX icon

Cutler Group’s Neurocrine Biosciences NBIX Stock Holding History

Cutler Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,600
Closed -$37K – 6138
2021
Q2 		$37K Buy
12,600
+9,600
+320% +$920K ﹤0.01% 2749
2021
Q1 		$27K Buy
+3,000
New +$315K ﹤0.01% 2948
2020
Q4 		– Sell
-2,500
Closed -$24K – 5272
2020
Q3 		$24K Hold
2,500
– – ﹤0.01% 2326
2020
Q2 		$14K Hold
2,500
– – ﹤0.01% 2638
2020
Q1 		$54K Buy
+2,500
New +$245K ﹤0.01% 1678
2019
Q4 		– Sell
-7,400
Closed -$97K – 4381
2019
Q3 		$97K Hold
7,400
– – 0.01% 1083
2019
Q2 		$136K Sell
7,400
-4,500
-38% -$369K 0.01% 924
2019
Q1 		$140K Buy
11,900
+400
+3% +$33.4K 0.01% 824
2018
Q4 		$227K Buy
11,500
+6,100
+113% +$584K 0.02% 573
2018
Q3 		$47K Sell
5,400
-600
-10% -$68.1K ﹤0.01% 1647
2018
Q2 		$2K Sell
6,000
-7,500
-56% -$671K ﹤0.01% 3603
2018
Q1 		$31K Sell
13,500
-14,600
-52% -$1.23M ﹤0.01% 1988
2017
Q4 		$69K Buy
28,100
+2,900
+12% +$198K ﹤0.01% 1629
2017
Q3 		$56K Sell
25,200
-4,100
-14% -$216K ﹤0.01% 2140
2017
Q2 		$47K Buy
29,300
+25,000
+581% +$1.21M ﹤0.01% 2562
2017
Q1 		$15K Sell
4,300
-22,000
-84% -$943K ﹤0.01% 3629
2016
Q4 		$87K Buy
26,300
+12,500
+91% +$566K ﹤0.01% 2025
2016
Q3 		$2K Sell
13,800
-4,900
-26% -$244K ﹤0.01% 5747
2016
Q2 		$6K Sell
18,700
-15,800
-46% -$727K ﹤0.01% 4760
2016
Q1 		$33K Buy
34,500
+6,600
+24% +$262K ﹤0.01% 2754
2015
Q4 		$45K Buy
+27,900
New +$1.42M ﹤0.01% 2580

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cutler Group's NBIX Position: Q3 2022 in Review

Cutler Group sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 124 shares — an estimated $12K sold.

Cutler Group first reported a position in NBIX in Q4 2015 and held it in 22 quarters. The position peaked at $2.85M in Q3 2017. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Cutler Group reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 124 Neurocrine Biosciences shares in Q3 2022, an estimated $12K.
  • Cutler Group first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 22 quarters.
  • Cutler Group's Neurocrine Biosciences position peaked at $2.85M in Q3 2017.
  • 466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.